Drug-protein conjugation and its immunological consequences.
about
Metabolism of hydralazine: relevance to drug-induced lupusDrug-dependent clearance of human platelets in the NOD/scid mouse by antibodies from patients with drug-induced immune thrombocytopeniaIncreased risk of erythema multiforme major with combination anticonvulsant and radiation therapies.Idiosyncratic drug reactions: a mechanistic evaluation of risk factorsFree radical theory of autoimmunityThe role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions.Bispecific small molecule-antibody conjugate targeting prostate cancer.Viral triggers for autoimmunity: is the 'glass of molecular mimicry' half full or half empty?Educational case series: Mechanisms of drug allergy.The generation, detection, and effects of reactive drug metabolites.Pathogen infection as a possible cause for autoimmune hepatitis.Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts.The effects of nutrition on chemical toxicity.Specific targets of covalent drug-protein interactions in hepatocytes and their toxicological significance in drug-induced liver injury.A history of drug metabolism in the United Kingdom.Immunopharmacology and adverse drug reactions.The role of reactive drug metabolites in immune-mediated adverse drug reactions.N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity.NMR and QSAR studies on the transacylation reactivity of model 1beta-O-acyl glucuronides. I: design, synthesis and degradation rate measurement.Nuclear magnetic resonance (NMR) and quantitative structure-activity relationship (QSAR) studies on the transacylation reactivity of model 1beta-O-acyl glucuronides. II: QSAR modelling of the reaction using both computational and experimental NMR paOxidation and adduct formation of xenobiotics in a microfluidic electrochemical cell with boron doped diamond electrodes and an integrated passive gradient rotation mixer.A general procedure for isotopic (deuterium) labelling of non-steroidal antiinflammatory 2-arylpropionic acids
P2860
Q28238389-124B6113-743A-4AC7-8341-70EB7A2EDEE9Q33390444-DD765738-7312-4CDE-BACC-8781A36F8D26Q33536015-21E659DC-383C-4C8E-ADAA-806C43C022EAQ34403403-9FAC09D6-01F3-43B1-8B71-79D99187B686Q34786280-9135936B-696A-4D78-8B5C-E96A0EE2790FQ36312078-E536AADB-8F81-4D9E-813A-B52D5D1A526DQ37276578-296EF9D3-5E2E-41F3-83B3-A456D10F38AFQ37588932-DEAB3838-D857-4273-B4C8-A0CA7E949B9EQ37885432-5B6E01AC-EB3D-4138-BBE5-E793DBA28423Q38054629-8AEA10F8-3F74-4769-89B9-9D77CD7A9649Q38218770-BCF11D39-A438-4018-99D6-6ACC03C01909Q38739489-E4691C18-8A5C-4F8C-AEB6-CCF9F274070BQ40603815-6ED3D963-EE29-4022-8565-B4BC978C1FE5Q40817414-CA96692B-263D-4AEE-A722-2D37C263F397Q40885948-3692C8CC-F385-48EC-A3DA-224E94EFAC1BQ40896729-B65671C9-1AF7-4917-88AF-9940EBB96808Q41656963-1C13F35E-3695-4C1B-9302-C5379F5B3980Q42000770-2043E726-7461-4AAF-8FA1-71729C9E04F3Q45281781-052A1552-6D06-40D3-A50B-4B199E04C431Q46375097-E4BA8BEA-851D-4513-A638-B7D78C093EE6Q46479890-25E60405-2EA8-4E60-ABB9-12A13A71A8ADQ57977644-30B75809-B334-40BD-884D-670FC15FC46C
P2860
Drug-protein conjugation and its immunological consequences.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Drug-protein conjugation and its immunological consequences.
@en
Drug-protein conjugation and its immunological consequences.
@nl
type
label
Drug-protein conjugation and its immunological consequences.
@en
Drug-protein conjugation and its immunological consequences.
@nl
prefLabel
Drug-protein conjugation and its immunological consequences.
@en
Drug-protein conjugation and its immunological consequences.
@nl
P2860
P1476
Drug-protein conjugation and its immunological consequences.
@en
P2093
Kitteringham NR
P2860
P304
P356
10.3109/03602539008991445
P407
P577
1990-01-01T00:00:00Z